These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 20832752)

  • 1. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma.
    Mir SE; De Witt Hamer PC; Krawczyk PM; Balaj L; Claes A; Niers JM; Van Tilborg AA; Zwinderman AH; Geerts D; Kaspers GJ; Peter Vandertop W; Cloos J; Tannous BA; Wesseling P; Aten JA; Noske DP; Van Noorden CJ; Würdinger T
    Cancer Cell; 2010 Sep; 18(3):244-57. PubMed ID: 20832752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WEE1 inhibition sensitizes osteosarcoma to radiotherapy.
    PosthumaDeBoer J; Würdinger T; Graat HC; van Beusechem VW; Helder MN; van Royen BJ; Kaspers GJ
    BMC Cancer; 2011 Apr; 11():156. PubMed ID: 21529352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe.
    De Witt Hamer PC; Mir SE; Noske D; Van Noorden CJ; Würdinger T
    Clin Cancer Res; 2011 Jul; 17(13):4200-7. PubMed ID: 21562035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokinetic effects of Wee1 disruption in pancreatic cancer.
    Chang Q; Chandrashekhar M; Ketela T; Fedyshyn Y; Moffat J; Hedley D
    Cell Cycle; 2016; 15(4):593-604. PubMed ID: 26890070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.
    Hirai H; Iwasawa Y; Okada M; Arai T; Nishibata T; Kobayashi M; Kimura T; Kaneko N; Ohtani J; Yamanaka K; Itadani H; Takahashi-Suzuki I; Fukasawa K; Oki H; Nambu T; Jiang J; Sakai T; Arakawa H; Sakamoto T; Sagara T; Yoshizumi T; Mizuarai S; Kotani H
    Mol Cancer Ther; 2009 Nov; 8(11):2992-3000. PubMed ID: 19887545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma.
    Harris PS; Venkataraman S; Alimova I; Birks DK; Balakrishnan I; Cristiano B; Donson AM; Dubuc AM; Taylor MD; Foreman NK; Reigan P; Vibhakar R
    Mol Cancer; 2014 Mar; 13():72. PubMed ID: 24661910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
    Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
    Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor.
    Mizuarai S; Yamanaka K; Itadani H; Arai T; Nishibata T; Hirai H; Kotani H
    Mol Cancer; 2009 Jun; 8():34. PubMed ID: 19500427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells.
    Toledo CM; Ding Y; Hoellerbauer P; Davis RJ; Basom R; Girard EJ; Lee E; Corrin P; Hart T; Bolouri H; Davison J; Zhang Q; Hardcastle J; Aronow BJ; Plaisier CL; Baliga NS; Moffat J; Lin Q; Li XN; Nam DH; Lee J; Pollard SM; Zhu J; Delrow JJ; Clurman BE; Olson JM; Paddison PJ
    Cell Rep; 2015 Dec; 13(11):2425-2439. PubMed ID: 26673326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells.
    Pappano WN; Zhang Q; Tucker LA; Tse C; Wang J
    BMC Cancer; 2014 Jun; 14():430. PubMed ID: 24927813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells.
    Mak JP; Man WY; Chow JP; Ma HT; Poon RY
    Oncotarget; 2015 Aug; 6(25):21074-84. PubMed ID: 26025928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line.
    Hashimoto O; Shinkawa M; Torimura T; Nakamura T; Selvendiran K; Sakamoto M; Koga H; Ueno T; Sata M
    BMC Cancer; 2006 Dec; 6():292. PubMed ID: 17177986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role for Wee1 in inhibition of G2-to-M transition through the cooperation of distinct human papillomavirus type 1 E4 proteins.
    Knight GL; Turnell AS; Roberts S
    J Virol; 2006 Aug; 80(15):7416-26. PubMed ID: 16840322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.
    Wang Y; Li J; Booher RN; Kraker A; Lawrence T; Leopold WR; Sun Y
    Cancer Res; 2001 Nov; 61(22):8211-7. PubMed ID: 11719452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Murine Wee1 plays a critical role in cell cycle regulation and pre-implantation stages of embryonic development.
    Tominaga Y; Li C; Wang RH; Deng CX
    Int J Biol Sci; 2006; 2(4):161-70. PubMed ID: 16810330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Wee1-like protein kinase to treat cancer.
    Stathis A; Oza A
    Drug News Perspect; 2010 Sep; 23(7):425-9. PubMed ID: 20862394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells.
    Hirose Y; Berger MS; Pieper RO
    Cancer Res; 2001 Aug; 61(15):5843-9. PubMed ID: 11479224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells.
    Kreahling JM; Gemmer JY; Reed D; Letson D; Bui M; Altiok S
    Mol Cancer Ther; 2012 Jan; 11(1):174-82. PubMed ID: 22084170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
    Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S
    Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma.
    Wu S; Wang S; Gao F; Li L; Zheng S; Yung WKA; Koul D
    Neuro Oncol; 2018 Jan; 20(1):78-91. PubMed ID: 29016926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.